Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621855 · ClinicalTrials.gov registry record · Phase 2
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,878
- Enrollment target
NCT00621855 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,878 participants.
The verdict
NCT00621855, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,878 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.
Interventions
- DRUG placebo
- DRUG dabigatran etexilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,878 participants |
| Start Date | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00621855
The ClinicalTrials.gov registry entry for NCT00621855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,878 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00621855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00621855 about?
NCT00621855 is a clinical study titled "RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome". The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new i...
What is the current status of trial NCT00621855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,878 participants. The study started on 2008-03.
What interventions are being tested in trial NCT00621855?
The interventions under investigation include: placebo (DRUG), dabigatran etexilate (DRUG).
Who is sponsoring clinical trial NCT00621855?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.